Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Trial details
- Registry ID
- NCT05721729
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose ExcursionsNCT05721729 | VOGX | Phase 2 | Completed | 2024-05-01Actual |
| Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia SubjectsNCT05541939 | VOGX | Phase 2 | Completed | 2023-02-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |